Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Martina Catalano; Giandomenico Roviello; Ilaria Camilla Galli; Raffaella Santi; Gabriella Nesi

doi:10.3389/fmed.2022.1014257

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Front Med (Lausanne). 2022 Dec 20:9:1014257. doi: 10.3389/fmed.2022.1014257. eCollection 2022.

Authors

Martina Catalano¹, Giandomenico Roviello², Ilaria Camilla Galli³, Raffaella Santi², Gabriella Nesi³

Affiliations

¹ School of Human Health Sciences, University of Florence, Florence, Italy.
² Department of Health Sciences, University of Florence, Florence, Italy.
³ Histopathology and Molecular Diagnostics, Careggi Teaching Hospital, Florence, Italy.

Abstract

Although immune checkpoint inhibitors (ICIs) have dramatically revolutionized the field of oncology over the last decade, severe immune-related adverse events (irAEs) are potentially life-threatening. In comparison with toxicities involving the skin, gastrointestinal tract and endocrine system, nephrotoxicity is less common but often underestimated due to difficult diagnosis. Management usually consists of treatment discontinuation and/or corticosteroid use. In this review, we summarize current knowledge of ICI-induced nephrotoxicity, evaluating drawbacks and future perspectives.

Keywords: ICI-induced acute kidney injury; immune checkpoint inhibitors; immune-related adverse events; multidisciplinary management; nephrotoxicity.

Publication types

Review